IL1B and neoplasm: This innovative strategy kills residual tumor cells directly through pyroptosis while releasing the tumor‐associated antigens, adenosine triphosphate (ATP), high‐mobility group box protein 1 (HMGB1), immune activating cytokines interleukin‐1β (IL‐1β) and interferon‐γ (IFN‐γ), thus improving the immunogenicity and modulating immunosuppression to promote the maturation of DCs and the infiltration of cytotoxic T cells, resulting in the efficient repression of tumor growth and postoperative recurrence (Scheme1).